Paper Details

  1. Home
  2. Paper Details

Successful treatment with avacopan (CCX168) in a pediatric patient with C3 glomerulonephritis.

Author: CappoliAndrea, Diomedi-CamasseiFrancesca, EmmaFrancesco, GargiuloAntonio, VivarelliMarina, ZottaFederica

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This abstract discusses C3 glomerulonephritis (C3GN), a subtype of C3 glomerulopathy (C3G), and the potential of avacopan, a C5aR antagonist, as a treatment option.
Paper Details　
Original Abstract of the Article :
C3 glomerulonephritis (C3GN) is a subtype of C3 glomerulopathy (C3G), characterized by dysregulation of the alternative pathway of complement and by dominant C3 by immunofluorescence on the kidney biopsy. There is no approved treatment for patients with C3G. Immunosuppressive drugs as well as biolog...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00467-023-06035-4

データ提供：米国国立医学図書館（NLM）

Avacopan: A New Oasis in the Desert of C3 Glomerulonephritis

C3 glomerulonephritis (C3GN), a rare and potentially serious kidney disease, can feel like a daunting desert, with limited treatment options. This study explores the use of avacopan (CCX168), a C5aR antagonist, in a pediatric patient with C3GN, offering a glimmer of hope for a new treatment approach.

Avacopan: A Promising New Frontier

The study highlights the potential of avacopan as a treatment for C3GN, demonstrating its effectiveness in a pediatric patient. The study's findings suggest that avacopan, like a spring of water in a barren desert, could offer a vital source of relief for individuals with this challenging condition.

A New Path for Treatment: Targeting the Complement System

This research offers hope for a new approach to treating C3GN, focusing on the complement system. The study's findings suggest that avacopan could potentially play a role in managing this complex and often debilitating disease.

Dr.Camel's Conclusion

This case study offers a promising glimpse into the potential of avacopan as a treatment for C3 glomerulonephritis, offering a new path to hope for individuals facing this challenging condition. Just as a camel navigates a desert seeking a source of water, so too do researchers explore new avenues for treating diseases, seeking solutions to improve patient outcomes.

Date :
  1. Date Completed 2023-11-07
  2. Date Revised 2023-11-07
Further Info :

Pubmed ID

37306717

DOI: Digital Object Identifier

10.1007/s00467-023-06035-4

Related Literature

Article Analysis
・Effects of avacopan
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.